# EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

> clinical trial · VERIFIED · 2026-06-11

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: PIK3CA-related Overgrowth Spectrum (PROS)

- Company: Novartis Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06997588

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.